RU2007135167A - Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака - Google Patents

Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака Download PDF

Info

Publication number
RU2007135167A
RU2007135167A RU2007135167/14A RU2007135167A RU2007135167A RU 2007135167 A RU2007135167 A RU 2007135167A RU 2007135167/14 A RU2007135167/14 A RU 2007135167/14A RU 2007135167 A RU2007135167 A RU 2007135167A RU 2007135167 A RU2007135167 A RU 2007135167A
Authority
RU
Russia
Prior art keywords
seq
antibody
amino acid
acid sequence
group
Prior art date
Application number
RU2007135167/14A
Other languages
English (en)
Russian (ru)
Inventor
Хесус ГОМЕС-НАВАРРО (US)
Хесус ГОМЕС-НАВАРРО
Чарльз Майкл БАУМ (US)
Чарльз Майкл БАУМ
Original Assignee
Пфайзер Продактс Инк. (Us)
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. (Us), Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк. (Us)
Publication of RU2007135167A publication Critical patent/RU2007135167A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2007135167/14A 2005-03-23 2006-03-03 Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака RU2007135167A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66465305P 2005-03-23 2005-03-23
US60/664,653 2005-03-23

Publications (1)

Publication Number Publication Date
RU2007135167A true RU2007135167A (ru) 2009-03-27

Family

ID=36680342

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007135167/14A RU2007135167A (ru) 2005-03-23 2006-03-03 Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака

Country Status (16)

Country Link
US (1) US20090074787A1 (cg-RX-API-DMAC7.html)
EP (1) EP1863532A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006265245A (cg-RX-API-DMAC7.html)
KR (1) KR20070104673A (cg-RX-API-DMAC7.html)
CN (1) CN101146553A (cg-RX-API-DMAC7.html)
AR (1) AR054237A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006227880A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607579A2 (cg-RX-API-DMAC7.html)
CA (1) CA2602316A1 (cg-RX-API-DMAC7.html)
IL (1) IL185491A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007011767A (cg-RX-API-DMAC7.html)
NZ (1) NZ561138A (cg-RX-API-DMAC7.html)
RU (1) RU2007135167A (cg-RX-API-DMAC7.html)
TW (1) TW200700083A (cg-RX-API-DMAC7.html)
WO (1) WO2006101692A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708026B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080040007A (ko) * 2005-09-20 2008-05-07 화이자 프로덕츠 인크. 티로신 키나제 억제제를 이용한 치료의 투여형 및 방법
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
WO2011045704A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2014182761A1 (en) * 2013-05-09 2014-11-13 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
KR101940430B1 (ko) * 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Il-18과 분자 표적 항체를 병용하는 암 치료약
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EP3256165B1 (en) * 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
EP3347380B1 (en) 2015-09-11 2024-09-25 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7173993B2 (ja) * 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
KR102371980B1 (ko) 2020-06-29 2022-03-08 인하대학교 산학협력단 췌장암 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP3663382B2 (ja) * 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US6599902B2 (en) * 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
WO2004029069A2 (en) * 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
NZ546001A (en) * 2003-10-02 2009-09-25 Pharmacia & Upjohn Co Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
BRPI0509274A (pt) * 2004-03-26 2007-09-04 Pfizer Prod Inc usos de anticorpos anti-ctla-4

Also Published As

Publication number Publication date
US20090074787A1 (en) 2009-03-19
EP1863532A1 (en) 2007-12-12
AU2006227880A1 (en) 2006-09-28
WO2006101692A1 (en) 2006-09-28
CA2602316A1 (en) 2006-09-28
BRPI0607579A2 (pt) 2009-09-15
CN101146553A (zh) 2008-03-19
TW200700083A (en) 2007-01-01
NZ561138A (en) 2009-06-26
AR054237A1 (es) 2007-06-13
IL185491A0 (en) 2008-01-06
MX2007011767A (es) 2007-10-18
KR20070104673A (ko) 2007-10-26
JP2006265245A (ja) 2006-10-05
ZA200708026B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
RU2007135167A (ru) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
JP2006265245A5 (cg-RX-API-DMAC7.html)
WO2021212638A1 (en) Conjugates of a cell-binding molecule with camptothecin analogs
CN107921144B (zh) 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
ES2701076T3 (es) Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
ES2939836T3 (es) Conjugados de moléculas de unión celular con agentes citotóxicos
AU2023200925A1 (en) Hydrophilic Linkers for Conjugate
CN105641707B (zh) 细胞毒素分子同细胞结合受体分子的共轭体
JP2023507190A5 (cg-RX-API-DMAC7.html)
JP2025013486A (ja) 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
RU2012133522A (ru) Новое применение соединений ил-1 бета
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
US20220001009A1 (en) Novel compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound
JP2021511372A5 (cg-RX-API-DMAC7.html)
JP2022513684A5 (cg-RX-API-DMAC7.html)
JP2010534685A (ja) チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ
RU2007134867A (ru) Терапия рака предстательной железы ctla4-антителами и гормональной терапией
AU2017228459A1 (en) Polymalic acid based nanoimmunoconjugates and uses thereof
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2021506817A5 (cg-RX-API-DMAC7.html)
JP2023502876A5 (cg-RX-API-DMAC7.html)
JP2025504558A (ja) Ｐｓｍａ標的化放射性医薬品およびチェックポイント阻害剤併用療法
JP2023072104A (ja) 抗体薬物複合体
JP2024521667A5 (cg-RX-API-DMAC7.html)